Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 43-50

  Cappelli, Laura C ^a   Gutierrez, Anna Kristina ^a   Baer, Alan N ^a   Albayda, Jemima ^a   Manno, Rebecca L ^a   Haque, Uzma ^a   Lipson, Evan J ^b   Bleich, Karen B ^a   Shah, Ami A ^a   Naidoo, Jarushka ^b   Brahmer, Julie R ^b   Le, Dung ^b   Bingham, Clifton O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INFLIXIMAB; IPILIMUMAB; METHOTREXATE; NIVOLUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; MALE; MELANOMA; METASTATIC MELANOMA; MIDDLE AGED; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SALIVARY GLAND DISEASE; SJOEGREN SYNDROME; SMALL CELL LUNG CANCER; SOLID TUMOR; SYNOVIAL FLUID; TALONAVICULAR JOINT; THYROIDITIS; ULTRASOUND; ARTHRITIS; BLOOD; CHEMICALLY INDUCED; SJOGREN'S SYNDROME; SYNOVITIS;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ARTHRITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; SJOGREN'S SYNDROME; SYNOVITIS;

EID: 84978959070     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209595     Document Type: Article

References (31)

1. Lee L, Gupta M, Sahasranaman S. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. J Clin Pharmacol 2016;56: 157-69.
2. WeberJS,D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16: 375-84.
3. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Eng J Med 2015;372: 2521-32.
4. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373: 1270-1.
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-23.
6. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372: 2018-28.
7. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373: 1803-13.
8. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372: 311-19.
9. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015;27: 450-61.
10. ClinialTrials.gov website: US National Institutes of Health. 2015 (accessed 27 Dec 2015).
11. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26: 2375-91.
12. Weber JS, Yang JC, Atkins MB, et al. Toxicities of Immunotherapy for the practitioner. J Clin Oncol 2015;33: 2092-9.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
14. Theander E, Mandl T. Primary Sjögren's syndrome: Diagnostic and prognostic value of salivary gland ultrasonography using a simplified scoring system. Arthritis Care Res (Hoboken) 2014;66: 1102-7.
15. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373: 123-35.
16. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372: 320-30.
17. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11: 155-64.
18. Bernardo SG, Moskalenko M, Pan M, et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 2013;23: 47-54.
19. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32: 1020-30.
20. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015;35: 76-83.
21. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373: 1627-39.
22. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373: 23-34.
23. Chan MM, Kefford RF, Carlino M, et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 2015;38: 37-9.
24. Bronstein Y, Ng CS, Hwu P, et al. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 2011;197: W992-1000.
25. Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 2012;35: 169-78.
26. Sheik Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: A novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 2015;151: 195-9.
27. Yoshioka M, Kambe N, Yamamoto Y, et al. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol 2015;42: 1008-9.
28. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheum 2014;66: 768-9.
29. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30: 2691-7.
30. Woodworth T, Furst DE, Alten R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: The Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol 2007;34: 1401-14.
31. Klair JS, Girotra M, Hutchins LF, et al. Ipilimumab-induced gastrointestinal toxicities: A management algorithm. Dig Dis Sci 2016. [Epub ahead of print].